Randomized Phase II Trial of Ustekinumab for GVHD Prevention in Matched Unrelated Donor Transplants: Primary Trial Results

Key Points

• Ustekinumab significantly reduces the occurrence of GVHD in treated subjects, providing hope for future protocols.
• The trial observed a GVHD incidence of 25% among treated versus 50% in control groups, supporting its effectiveness.
• Conducted as a randomized phase II trial to evaluate the efficacy of ustekinumab in preventing GVHD following transplants.
• These findings highlight potential benefits for patients receiving unrelated donor organs, indicating a shift in transplantation practices.